Commercial Supply Bedaquiline Related Intermediates:
3-Benzyl-6-Bbromo-2-Mmethoxyquinoline CAS: 654655-69-3
3-Benzyl-6-Bromo-2-Chloroquinoline CAS: 654655-68-2
3-(Dimethylamino)-1-(Naphthalen-1-yl)propan-1-one Hydrochloride CAS: 5409-58-5
Bedaquiline Fumarate CAS: 845533-86-0
| Chemical Name | 3-Benzyl-6-Bromo-2-Chloroquinoline |
| Synonyms | 6-Bromo-2-Chloro-3-(Phenylmethyl)quinoline; Bedaquiline Impurity B; Bedaquiline Fumarate Impurity 5 |
| CAS Number | 654655-68-2 |
| CAT Number | RF-PI107 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C₁₆H₁₁BrClN |
| Molecular Weight | 332.62 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White or Light Yellow Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Melting Point | 100.0~120.0℃ |
| Moisture (K.F) | ≤0.50% |
| Residue on ignition | ≤0.50% |
| Total Impurities | ≤1.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Bedaquiline Fumarate (CAS: 845533-86-0) |
3-Benzyl-6-bromo-2-chloroquinoline (CAS: 654655-68-2) is a main intermediate of Bedaquiline Fumarate (CAS: 845533-86-0). Bedaquiline Fumarate is a diarylquinone drug developed by Janssen Pharmaceutical. The drug, which was approved in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB), was developed in partnership with Johnson & Johnson and represents the first new tuberculosis therapy approved in over four decades. Bedaquiline Fumarate used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of th mycobacteria.